Gates Vascular Institute

Recor Medical Announces U.S. Launch and First Commercial Cases of Paradise Ultrasound Renal Denervation Therapy

Retrieved on: 
Friday, November 10, 2023

Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced the first commercial uses of Recor’s Paradise™ Ultrasound Renal Denervation (uRDN) system for the treatment of hypertension, the first FDA approved renal denervation therapy in the United States.

Key Points: 
  • Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced the first commercial uses of Recor’s Paradise™ Ultrasound Renal Denervation (uRDN) system for the treatment of hypertension, the first FDA approved renal denervation therapy in the United States.
  • The first commercial procedures took place at NewYork-Presbyterian/Columbia University Irving Medical Center in New York City by Drs.
  • Paradise uRDN delivers two to three doses of 360-degree ultrasound energy — lasting seven seconds each — through the main renal arteries to the surrounding nerves.
  • “This new renal denervation technology for a high-risk patient population – individuals with difficult to control hypertension – has been long awaited.

NVR, INC. ANNOUNCES FOUNDER DWIGHT C. SCHAR AWARDED LIFETIME ACHIEVEMENT AWARD

Retrieved on: 
Friday, December 8, 2023

RESTON, Va., Dec. 8, 2023 /PRNewswire/ -- NVR, Inc. (NYSE: NVR), one of the nation's largest homebuilding and mortgage banking companies, announced that Dwight C. Schar was awarded the Lifetime Achievement Award by the Washington Business Journal at a ceremony held in Washington D.C. on December 7, 2023.

Key Points: 
  • RESTON, Va., Dec. 8, 2023 /PRNewswire/ -- NVR, Inc. (NYSE: NVR), one of the nation's largest homebuilding and mortgage banking companies, announced that Dwight C. Schar was awarded the Lifetime Achievement Award by the Washington Business Journal at a ceremony held in Washington D.C. on December 7, 2023.
  • Mr. Schar received this award in recognition of his tremendous impact on the Washington DC area economy.
  • Under Mr. Schar's leadership, NVR has built over 100,000 homes in the Washington DC area since its founding in 1980, creating countless jobs as a result.
  • The Company would like to congratulate Dwight on receiving this well-deserved honor.

Database Reveals Italy's Booming Data Center Market with 63 Existing and 9 Upcoming Facilities

Retrieved on: 
Friday, July 21, 2023

DUBLIN, July 21, 2023 /PRNewswire/ -- The "Italy Existing & Upcoming Data Center Portfolio" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 21, 2023 /PRNewswire/ -- The "Italy Existing & Upcoming Data Center Portfolio" report has been added to ResearchAndMarkets.com's offering.
  • The "Italy Data Center Market Portfolio Analysis" database provides critical insights into each data center facility.
  • The database includes a comprehensive list of investors and operators actively contributing to Italy's data center market.
  • For those seeking comprehensive insights into Italy's thriving data center market, this database is an invaluable tool for making informed decisions.

NVR, INC. ANNOUNCES FOUNDER DWIGHT C. SCHAR INDUCTED INTO THE NAHB NATIONAL HOUSING HALL OF FAME

Retrieved on: 
Tuesday, June 6, 2023

RESTON, Va., June 6, 2023 /PRNewswire/ -- NVR, Inc. (NYSE: NVR), one of the nation's largest homebuilding and mortgage banking companies, announced that Dwight C. Schar was inducted into the National Association of Homebuilders (NAHB) National Housing Hall of Fame at a ceremony held at the National Housing Center in Washington D.C. on June 6, 2023.

Key Points: 
  • RESTON, Va., June 6, 2023 /PRNewswire/ -- NVR, Inc. (NYSE: NVR), one of the nation's largest homebuilding and mortgage banking companies, announced that Dwight C. Schar was inducted into the National Association of Homebuilders (NAHB) National Housing Hall of Fame at a ceremony held at the National Housing Center in Washington D.C. on June 6, 2023.
  • Mr. Schar began his homebuilding career with Ryan Homes in 1968.
  • Mr. Schar left Ryan Homes to start NVHomes and later founded NVR when NVHomes acquired Ryan Homes.
  • Mr. Schar was instrumental in transforming NVR into the nation's third largest homebuilder in terms of market capitalization as well as achieving industry leading financial returns.

GRESSER ELECTED PRESIDENT OF EB-5 TRADE ASSOCIATION - INVEST IN THE USA (IIUSA)

Retrieved on: 
Monday, June 5, 2023

BUFFALO, N.Y., June 5, 2023 /PRNewswire/ -- Bill Gresser, President of EB-5 New York State was elected President of Invest in the USA ( IIUSA ) at the association's Annual Membership Meeting in San Diego on May 23, 2023.

Key Points: 
  • BUFFALO, N.Y., June 5, 2023 /PRNewswire/ -- Bill Gresser, President of EB-5 New York State was elected President of Invest in the USA ( IIUSA ) at the association's Annual Membership Meeting in San Diego on May 23, 2023.
  • IIUSA is the national, non-profit trade association that represents the EB-5 Regional Center industry across the US and globally.
  • Mr. Gresser joined IIUSA in 2009 and has previously served the association in various capacities including as Chairman of the Public Policy Committee and Vice President.
  • IIUSA also announced that Noreen Hogan of CMB Regional Centers was elected Vice President and Adam Greene of Peachtree Group was elected Secretary-Treasurer.

Synchron to Begin Patient Enrollment for the COMMAND Trial of Brain-Computer Interface at Gates Vascular Institute

Retrieved on: 
Monday, March 20, 2023

The COMMAND trial is being conducted under the first investigational device exemption (IDE) awarded by the FDA to a company assessing a permanently implanted BCI.

Key Points: 
  • The COMMAND trial is being conducted under the first investigational device exemption (IDE) awarded by the FDA to a company assessing a permanently implanted BCI.
  • The new site at Gates Vascular Institute marks the third approved COMMAND trial location, joining Mount Sinai Health System in New York and the University of Pittsburgh Medical Center.
  • The FDA granted Breakthrough Device designation to Synchron in August 2020 and an IDE in July 2021.
  • There is no guarantee of participation and principal investigators make the final determination of patient eligibility.

NovaSignal Donates NovaGuide™ 2 Intelligent Ultrasound to The Jacobs Institute to Advance Stroke Research

Retrieved on: 
Tuesday, February 28, 2023

A non-profit vascular medical technology innovation center, the Jacobs Institute operates at the forefront of developing the next generation of medical technology for the treatment of vascular disease.

Key Points: 
  • A non-profit vascular medical technology innovation center, the Jacobs Institute operates at the forefront of developing the next generation of medical technology for the treatment of vascular disease.
  • The robotic NovaGuide 2 Intelligent Ultrasound makes it easier for healthcare professionals to monitor patients during medical procedures.
  • “Vascular disease research continues to evolve and advance because of companies like NovaSignal,” said Adnan H. Siddiqui, MD, Ph.D., CEO/CMO of the Jacobs Institute and Director of Neurosurgical Stroke Service for Kaleida Health.
  • “We’re honored to receive this donation and to continue the important research about stroke related events following cardiac procedures.

MediPines Adds Three Global Thought Leaders to its Medical and Scientific Advisory Board

Retrieved on: 
Tuesday, March 1, 2022

Dr. Sieck is a Vernon F. and Earline D. Endowed Professor and Distinguished Investigator at the Mayo Clinic School of Medicine and Science.

Key Points: 
  • Dr. Sieck is a Vernon F. and Earline D. Endowed Professor and Distinguished Investigator at the Mayo Clinic School of Medicine and Science.
  • MediPines technology is a highly innovative and broadly applicable approach that pushes the boundaries of respiratory science, said Dr. Sieck.
  • We are honored to welcome Dr. Sieck, Dr. Zlupko and Dr. Raney to our board of esteemed clinical thought leaders, said MediPines CEO Steve Lee.
  • MediPines existing Medical and Scientific Advisory Board of experts already includes John B.